Market news

Xencor (XNCR) has an average rating of overweight and mean price target of $31.25, according to anal

Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.

PASADENA, Calif., September 02, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.

Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.

Xencor (XNCR) delivered earnings and revenue surprises of +64.63% and +337.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

PASADENA, Calif., August 05, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026.

Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.

Xencor (XNCR) shares were up about 10% in Thursday trading after the company said it has reached a s

PASADENA, Calif., July 29, 2026--Xencor, Inc. (NASDAQ:XNCR) ("Xencor"), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced its agreement with Alexion Pharma International Operations Limited, an Irish limited company ("Alexion"), to resolve a commercial dispute related to U.S. royalties on Ultomiris® (ravulizumab-cwvz) (the "Settlement Agreement").

Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

PASADENA, Calif., July 17, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) Congress 2026, to be held October 23-27